Darwin Global Management »

Aeglea Biotherapeutics shares owned by Darwin Global Management

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $18M 473k 37.93

More positions owned by Darwin Global Management

Vaxcyte (PCVX)
Nuvalent Inc-a (NUVL)
Keros Therapeutics (KROS)
Biohaven (BHVN)
Alpine Immune Sciences (ALPN)
Beam Therapeutics (BEAM)
Apogee Therapeutics (APGE)
Xencor (XNCR)
Spyre Therapeutics Com New (SYRE)
Elevation Oncology (ELEV)
Tourmaline Bio (TRML)
Merck & Co (MRK)

View all positions for Darwin Global Management

Top funds holding Aeglea Biotherapeutics

FMR
Perceptive Advisors
VR Adviser
Commodore Capital
venBio Select Advisor
Adage Capital Partners GP
Franklin Resources
Citadel Advisors
Wellington Management Company
BlackRock
Braidwell
Vanguard Group
Darwin Global Management
Farallon Capital Management
First Turn Management

View all funds holding Aeglea Biotherapeutics